Vericel Corporation (VCEL) Stock Price
VCELStock
$40.13+15.48%52W
Market Cap$2.05B
P/E124.41x
PEG Ratio2.19
Div yield—
Beta1.06
VCEL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)4.29%
Price vs S&P 500 (4W)2.79%
PEG Ratio2.19
VGM Score57.96
P/E Ratio (Annual)124.41x
VCEL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.03 | $0.04 | +249.98%(+$0.07) | |
| Q1 2026 | -$0.16 | -$0.12 | +23.41%(+$0.04) | |
| Q4 2025 | $0.38 | $0.45 | +17.80%(+$0.07) | |
| Q3 2025 | -$0.01 | $0.10 | +850.19%(+$0.11) | |
| Q2 2025 | -$0.04 | -$0.01 | +72.73%(+$0.03) |
VCEL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.21
4.21
4.21
4.21
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
VCELVericel Corporation | D | B | B | 6.7x | 22.9% | 74.6% | 38.9% | $40.13 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Vericel Corporation
Vericel is a biopharmaceutical company specializing in advanced cell therapies for sports medicine and severe burn care in the U.S. market. Its portfolio includes MACI (autologous cultured chondrocytes) for cartilage repair, Epicel (cultured epidermal autografts) for burn treatment, and NexoBrid. The company handles the full value chain from research and development through manufacturing and distribution.